Oxidative stress and ROS-mediated cellular events in RSV infection: potential protective roles of antioxidants

被引:0
作者
Xue Yang
Xue Liu
Yujun Nie
Fei Zhan
Bin Zhu
机构
[1] Affiliated Hospital of Hubei University of Arts and Science,Department of Pediatrics, Xiangyang Central Hospital
来源
Virology Journal | / 20卷
关键词
Respiratory syncytial virus; Oxidative stress; Reactive oxygen species; Nrf2; NLRP3; NETs; HMGB1;
D O I
暂无
中图分类号
学科分类号
摘要
Respiratory syncytial virus (RSV), a member of the Pneumoviridae family, can cause severe acute lower respiratory tract infection in infants, young children, immunocompromised individuals and elderly people. RSV is associated with an augmented innate immune response, enhanced secretion of inflammatory cytokines, and necrosis of infected cells. Oxidative stress, which is mainly characterized as an imbalance in the production of reactive oxygen species (ROS) and antioxidant responses, interacts with all the pathophysiologic processes above and is receiving increasing attention in RSV infection. A gradual accumulation of evidence indicates that ROS overproduction plays an important role in the pathogenesis of severe RSV infection and serves as a major factor in pulmonary inflammation and tissue damage. Thus, antioxidants seem to be an effective treatment for severe RSV infection. This article mainly reviews the information on oxidative stress and ROS-mediated cellular events during RSV infection for the first time.
引用
收藏
相关论文
共 562 条
  • [1] Barbati F(2020)Epidemiology of respiratory syncytial virus-related hospitalization over a 5-year period in Italy: evaluation of seasonality and age distribution before vaccine introduction Vaccines (Basel) 8 15-2064
  • [2] Moriondo M(2022)Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis Lancet 399 2047-16
  • [3] Pisano L(2021)Current state of respiratory syncytial virus disease and management Infect Dis Ther 10 5-520
  • [4] Li Y(2020)Update on current views and advances on RSV infection (Review) Int J Mol Med 46 509-2021
  • [5] Wang X(2022)Respiratory syncytial virus-associated hospitalisation in children aged ≤ 5 years: a scoping review of literature from 2009 to 2021 ERJ Open Res. 8 00593-801
  • [6] Blau DM(2023)Use of respiratory syncytial virus vaccines in older adults: recommendations of the advisory committee on immunization practices—United States, 2023 MMWR Morb Mortal Wkly Rep 72 793-53
  • [7] Chatterjee A(2022)Development of mRNA vaccines against respiratory syncytial virus (RSV) Cytokine Growth Factor Rev 68 37-634
  • [8] Mavunda K(2023)FDA approves maternal RSV vaccine JAMA 86 628-846
  • [9] Krilov LR(2019)Six-monthly palivizumab prophylaxis effectively reduced RSV-associated hospitalization rates of preterm infants in a subtropical area: a population-based cohort study Pediatr Res 11 839-778
  • [10] Mammas IN(2023)ACIP update: RSV prevention and updated recommendations on other vaccines Pediatrics 37 768-R462